Clinical Challenges of Immune Checkpoint Inhibitors

被引：414

作者：

de Miguel, Maria ^{[1
]}

Calvo, Emiliano ^{[1
]}

机构：

[1] Hosp Univ HM Sanchinarro, Ctr Integral Oncol Clara Camp, START Madrid HM CIOCC, Calle Ona 10, Madrid 28050, Spain

来源：

CANCER CELL | 2020年 / 38卷 / 03期

关键词：

METASTATIC UROTHELIAL CARCINOMA; ANTI-PD-1; ANTIBODY; RESPONSE CRITERIA; ADVANCED MELANOMA; OPEN-LABEL; PHASE-I; NIVOLUMAB; THERAPY; SAFETY; IPILIMUMAB;

D O I：

10.1016/j.ccell.2020.07.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Even though the immuno-oncology (IO) era has achieved many successes, some signs of research development deceleration are arising. Recently, the number of FDA immunotherapy approvals has decreased concurrently with a decline in the relative number of patients recruited to these trials. Identifying the unique features of IO treatments and taking them into consideration on clinical research will lead to a better evaluation of these agents and patient outcomes. In this review, we discuss current challenges and new potential approaches to implement rationally designed clinical trials of IO drugs, particularly those targeting immune checkpoints.

引用

页码：326 / 333

页数：8

共 60 条

[1]

[Anonymous], 2020, CANC CELL, V38, P331

[2]

[Anonymous], 2017, ANN ONCOL, DOI DOI 10.1093/ANNONC/MDX380.002

[3]

Antonia SJ, 2016, ANN ONCOL, V27

[4] Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer [J].

Basak, Edwin A. ;

Koolen, Stijn L. W. ;

Hurkmans, Daan P. ;

Schreurs, Marco W. J. ;

Bins, Sander ;

Oomen-de Hoop, Esther ;

Wijkhuijs, Annemarie J. M. ;

den Besten, Ilse ;

Sleijfer, Stefan ;

Debets, Reno ;

van der Veldt, Astrid A. M. ;

Aerts, Joachim G. J., V ;

Mathijssen, Ron H. J. .

EUROPEAN JOURNAL OF CANCER, 2019, 109 :12-20

[5] Novel patterns of response under immunotherapy [J].

Borcoman, E. ;

Kanjanapan, Y. ;

Champiat, S. ;

Kato, S. ;

Servois, V. ;

Kurzrock, R. ;

Goel, S. ;

Bedard, P. ;

Le Tourneau, C. .

ANNALS OF ONCOLOGY, 2019, 30 (03) :385-396

[6] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[7] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[8]

Calvo E., 2018, 2018 SITC ANN M

[9] Hyperprogressive disease: recognizing a novel pattern to improve patient management [J].

Champiat, Stephane ;

Ferrara, Roberto ;

Massard, Christophe ;

Besse, Benjamin ;

Marabelle, Aurelien ;

Soria, Jean-Charles ;

Ferte, Charles .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :748-762

[10] Early-phase clinical drug development of novel agents: a changing paradigm [J].

de Miguel, M. ;

Calvo, E. .

ANNALS OF ONCOLOGY, 2019, 30 (07) :1033-1037

← 1 2 3 4 5 6 →